Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks .

How have BIOVF shares performed in 2023?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $21.15 on January 1st, 2023. Since then, BIOVF stock has decreased by 0.5% and is now trading at $21.05. View the best growth stocks for 2023 here .

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 570,700 shares, an increase of 8.5% from the October 15th total of 526,200 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is currently 1,426.8 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest .

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $478.11 million for the quarter, compared to analyst estimates of $443.96 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 10.85% and a net margin of 13.05%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Swedish Orphan Biovitrum AB (publ) Stock Price, News & Analysis (OTCMKTS:BIOVF)

$21.05

0.00 (0.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $21.05
▼
$21.05
50-Day Range: $18.58
▼
$21.05
52-Week Range: $18.25
▼
$26.48

Volume: N/A
Average Volume: 76 shs
Market Capitalization: $6.21 billion

P/E Ratio: 24.20
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Headlines Short Interest

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOVF Stock News Headlines

November 23, 2023 | morningstar.com

Swedish Orphan Biovitrum AB BIOVF

November 1, 2023 | finance.yahoo.com

Sobi has completed the issuances of series C shares

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 30, 2023 | msn.com

Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17B

October 30, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates

October 30, 2023 | finance.yahoo.com

Sobi publishes Q3 2023 report: Strong revenue and solid performance

October 27, 2023 | finance.yahoo.com

Reminder: Invitation: Sobi's Q3 2023 report

October 18, 2023 | finance.yahoo.com

Invitation: Sobi's Q3 2023 report

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 15, 2023 | finance.yahoo.com

Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia

September 8, 2023 | finance.yahoo.com

Sobi KOL investor event: Advancing the standard of care in haemophilia

August 29, 2023 | finance.yahoo.com

Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?

August 22, 2023 | finance.yahoo.com

Sobi resolves on a rights issue of approximately SEK 6,024 million

August 15, 2023 | finance.yahoo.com

Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)

July 19, 2023 | tmcnet.com

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

July 18, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates

July 18, 2023 | prnewswire.com

Sobi publishes Q2 2023 report: Growth and pipeline expansion

July 17, 2023 | markets.businessinsider.com

Swedish Orphan Biovitrum AB earnings: here's what Wall Street expects

July 14, 2023 | finance.yahoo.com

Sobi KOL investor event: the journey for Vonjo®

July 11, 2023 | finance.yahoo.com

Invitation: Sobi's Q2 2023 report

June 25, 2023 | finance.yahoo.com

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

June 24, 2023 | finance.yahoo.com

Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

June 20, 2023 | finance.yahoo.com

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme

June 2, 2023 | finance.yahoo.com

Sobi to present new data at the 2023 EHA congress

May 30, 2023 | finance.yahoo.com

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

May 30, 2023 | finance.yahoo.com

Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

May 19, 2023 | finance.yahoo.com

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

See More Headlines

Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: N/A
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BIOVF
CUSIP: N/A
CIK: N/A
Web: www.sobi.com
Phone: (468) 697-2000
Fax: N/A
Employees: 1,612
Year Founded: 2001

Profitability

EPS (Most Recent Fiscal Year): $0.87
Trailing P/E Ratio: 24.20
Forward P/E Ratio: 22.88
P/E Growth: N/A
Net Income: $261.43 million
Net Margins: 13.05%
Pretax Margin: 19.83%
Return on Equity: 10.85%
Return on Assets: 4.94%

Debt

Debt-to-Equity Ratio: 0.61
Current Ratio: 0.59
Quick Ratio: 0.37

Sales & Book Value

Annual Sales: $1.86 billion
Price / Sales: 3.33
Cash Flow: $1.88 per share
Price / Cash Flow: 11.19
Book Value: $8.91 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 295,150,000
Free Float: N/A
Market Cap: $6.21 billion
Optionable: Not Optionable
Beta: 0.47

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Guido Oelkers (Age 58)
CEO & President
Comp: $22.78M
Mr. Henrik Stenqvist (Age 56)
Chief Financial Officer
Mr. Torbjörn Hallberg (Age 54)
General Counsel & Head of Legal Affairs
Mr. Daniel Rankin (Age 43)
Head of Strategy & Corporate Development
Pablo de Mora (Age 55)
Head of Global Marketing & Access
Ms. Lena Bjurner (Age 55)
Head of Human Resources
Mr. Armin Reininger M.D. (Age 66)
Ph.D., Senior Scientific & Medical Advisor
Mr. Norbert Oppitz (Age 56)
Head of International
Mr. Sofiane Fahmy (Age 51)
Head of Europe
Mr. Duane H. Barnes (Age 63)
Head of North America

Key Competitors

View All Competitors

BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings or view top-rated stocks.
How have BIOVF shares performed in 2023?: Swedish Orphan Biovitrum AB (publ)'s stock was trading at $21.15 on January 1st, 2023. Since then, BIOVF stock has decreased by 0.5% and is now trading at $21.05.
View the best growth stocks for 2023 here.
Are investors shorting Swedish Orphan Biovitrum AB (publ)?: Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 570,700 shares, an increase of 8.5% from the October 15th total of 526,200 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is currently 1,426.8 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?: Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $478.11 million for the quarter, compared to analyst estimates of $443.96 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 10.85% and a net margin of 13.05%.
How do I buy shares of Swedish Orphan Biovitrum AB (publ)?: Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial